New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 19, 2014
08:39 EDTCPXXCelator Pharmaceuticals initiates PK/PD clinical study of CPX-351
Celator Pharmaceuticals announced that the first patient has been enrolled in a Phase 2 pharmacokinetic and pharmacodynamics, or PK/PD, study evaluating the effects of CPX-351 Liposome Injection on cardiac repolarization in adult patients with acute hematologic malignancies, including acute myeloid leukemia, or AML, acute lymphoblastic leukemia, or ALL, and myelodysplastic syndrome, or MDS. This study will also include patients with moderate baseline hepatic and renal impairment, extending the range of safety and pharmacokinetic observations to this important group of patients.
News For CPXX From The Last 14 Days
Check below for free stories on CPXX the last two weeks.
Sign up for a free trial to see the rest of the stories you've been missing.
September 15, 2014
08:38 EDTCPXXCelator Pharmaceuticals announces publication of preclinical data for CPX-351
Subscribe for More Information
September 5, 2014
07:08 EDTCPXXCelator Pharmaceuticals initiated with a Buy at H.C. Wainwright
Subscribe for More Information

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use